CORONA Remedies Limited (NSE:CORONA)
2,236.70
-19.50 (-0.86%)
At close: Nov 19, 2026
CORONA Remedies Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, CORONA Remedies stock has a consensus rating of "Strong Buy" and an average price target of ₹2,495. The average 1-year stock price forecast is 11.53% higher than the current stock price, while the lowest is ₹2,345 (+4.84%) and the highest is ₹2,619 (+17.09%).
Price Target: ₹2,495 (+11.53%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CORONA Remedies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
17.25B
from 14.03B
Increased by 22.94%
Revenue Next Year
19.76B
from 17.25B
Increased by 14.56%
EPS This Year
40.10
from 32.67
Increased by 22.72%
EPS Next Year
52.27
from 40.10
Increased by 30.34%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.